Early trial halted: testing radiation plus new drug for tough cancers
NCT ID NCT05491317
Summary
This early-stage trial tested whether combining a new drug called GEN1042 with radiation therapy, with or without another immunotherapy drug (pembrolizumab), is safe and can help shrink tumors in people with advanced solid cancers that have spread. The study was for adults whose cancer had progressed despite standard treatments and who were eligible for palliative radiation. The trial was terminated early after enrolling 13 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CNS TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.